XERIS BIOPHARMA HOLDINGS, INC. (XERS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 189.57M USD | Liabilities, Current |
| Cash and equivalents | 121.75M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 58.10M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 80.93M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $189.57M | $121.75M | (m) | $58.10M | $80.93M | (m) |
| 2026-03-31 | (m) | $118.59M | $111.75M | (m) | $56.30M | $74.23M | (m) |
| 2025-12-31 | (m) | $109.57M | $111.04M | (m) | $51.05M | $68.67M | (m) |
| 2025-09-30 | (m) | $116.20M | $91.60M | (m) | $53.75M | $67.46M | (m) |
| 2025-06-30 | (m) | $95.17M | $59.28M | (m) | $53.05M | $67.28M | (m) |
| 2025-03-31 | (m) | $95.07M | $58.44M | (m) | $46.33M | $52.69M | (m) |
| 2024-12-31 | (m) | $100.44M | $71.62M | (m) | $40.41M | $48.17M | (m) |
| 2024-09-30 | (m) | $91.01M | $59.23M | (m) | $41.14M | $45.12M | (m) |
| 2024-06-30 | (m) | $75.49M | $57.60M | (m) | $42.44M | $42.98M | (m) |
| 2024-03-31 | (m) | $73.08M | $62.69M | (m) | $37.41M | $40.88M | (m) |
| 2023-12-31 | (m) | $95.19M | $67.45M | (m) | $39.20M | $38.84M | (m) |
| 2023-09-30 | (m) | $87.04M | $46.14M | (m) | $45.97M | $38.14M | (m) |
| 2023-06-30 | (m) | $79.68M | $46.17M | (m) | $30.23M | $36.54M | (m) |
| 2023-03-31 | (m) | $81.42M | $50.98M | (m) | $30.86M | $29.04M | (m) |
| 2022-12-31 | (m) | $73.62M | $121.97M | (m) | $30.83M | $24.73M | (m) |
| 2022-09-30 | (m) | $68.56M | $84.11M | (m) | $27.52M | $20.12M | (m) |
| 2022-06-30 | (m) | $64.55M | $95.34M | (m) | $25.76M | $17.89M | (m) |
| 2022-03-31 | (m) | $66.49M | $103.77M | (m) | $23.38M | $16.87M | (m) |
| 2021-12-31 | (m) | $79.04M | $67.27M | (m) | $17.46M | $18.12M | (m) |
| 2021-09-30 | (m) | $37.28M | $59.49M | (m) | (m) | $14.24M | (m) |
| 2020-12-31 | (m) | $28.21M | $37.60M | (m) | (m) | $8.35M | (m) |
| 2020-09-30 | (m) | (m) | $37.89M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $19.52M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |